Tuesday, October 8, 2024

BioAI Partners with Arbele Bio to Enhance Predictive AI in Oncology Trials

Related stories

Credo AI Launches Integrations Hub

Credo AI, the global pioneer of the AI governance...

Drone Nerds Adds Deepthink S8 Low-Light Camera to Its Enterprise Lineup

Drone Nerds, one of North America’s largest retailers, distributors,...

TurboDocx Writer Now Available on Microsoft AppSource

TurboDocx, a leading provider of AI-powered document generation solutions,...

Baker Tilly Acquires Alirrium, Expanding RPA and AI Capabilities

Leading advisory, tax and assurance firm Baker Tilly is...

OVHcloud and F5 Deliver Advanced Multicloud Application Security

OVHcloud® US, a global cloud player and leading European cloud...
spot_imgspot_img

BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, has announced a strategic partnership with Arbele, a biopharmaceutical company dedicated to developing novel immunotherapeutic platforms for gastrointestinal cancers.

The collaboration aims to leverage BioAI’s PredictX platform to develop AI-based models using Arbele’s clinical trial data, with a focus on colorectal cancer (CRC) biomarker screening. The goal is to create a companion diagnostic test for Arbele’s drug assets, enhancing patient selection through advanced AI technology.

“By joining forces with Arbele, we are excited to apply our novel AI platform and expertise to accelerate the development of innovative treatment options for gastrointestinal cancers,” said Thomas Colarusso, CEO of BioAI. “This partnership underscores our commitment to revolutionizing personalized medicine through cutting-edge machine learning.”

Also Read: Genpact Named Leader in 2024 Life Sciences Digital Services

Arbele’s CEO & Founder, Dr. John Luk, commented, “BioAI’s machine learning capabilities offer a transformative approach to biomarker identification and patient stratification. This collaboration is a critical step in improving outcomes for patients with high mortality cancers.”

The initial phase of the partnership will focus on developing a prototype machine learning classifier model for quantifying CDH17 expression patterns in CRC samples, using a combination of H&E (hematoxylin and eosin) and IHC (immunohistochemistry) stained images. This initiative aims to standardize and improve the pathologic assessment of treatment response biomarkers to facilitate more effective patient selection for Arbele‘s specific therapeutic programs. Both companies expect that this collaboration will pave the way for future advances in precision medicine, ultimately benefiting patients with gastrointestinal cancers.

BioAI is a leading provider of multimodal AI for digital health in precision medicine, offering world-leading machine learning technology to develop digital biomarkers and H&E based predictive models. They partner with leading pharmaceutical, biotechnology, clinical laboratories, and academic cancer centers around the world. With the PredictX Platform, BioAI aims to revolutionize personalized medicine by improving drug efficacy and patient outcomes.

SOURCE: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img